Open access
Open access
Powered by Google Translator Translator

Cardiology

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

23 Nov, 2020 | 09:46h | UTC

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines – Journal of the American College of Cardiology

Executive summary: 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines – Journal of the American College of Cardiology

Key perspectives: 2020 AHA/ACC Guideline for Hypertrophic Cardiomyopathy

News release: Hypertrophic cardiomyopathy guideline encourages shared decision-making – American College of Cardiology

 


Opinion: Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy

20 Nov, 2020 | 08:37h | UTC

Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy – JAMA

 


NICE Guideline: Acute coronary syndromes

19 Nov, 2020 | 09:24h | UTC

Acute coronary syndromes – National Institute for Health and Care Excellence

Visual summary: STEMI

Visual summary: NSTEMI/unstable angina

Visual summary: Cardiac rehabilitation and secondary prevention

 


#AHA20 [not published yet] Randomized trial: After drug-eluting stent implantation, one-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy was noninferior to 6-12 months of DAPT

19 Nov, 2020 | 09:21h | UTC

One-Month Dual Antiplatelet Therapy Followed by Aspirin Monotherapy After Drug-Eluting Stent Implantation – One-Month DAPT – American College of Cardiology

Commentary: Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT – TCTMD

 


#AHA20 – Two studies show lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy

18 Nov, 2020 | 09:11h | UTC

Study 1: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation – New England Journal of Medicine

Study 2: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation – New England Journal of Medicine

Commentaries: EARLY AF and STOP AF Put Electrophysiology at a Crossroads – Medscape (free registration required) AND EARLY-AF: First-line Ablation Beats Meds for Recent Paroxysmal A-fib – TCTMD

 

Commentary on Twitter (thread – click for more)


#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo

18 Nov, 2020 | 09:08h | UTC

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – SCORED – American College of Cardiology

 


#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and Recent Worsening Heart Failure. Diarrhea and severe hypoglycemia were more common with sotagliflozin than with placebo

18 Nov, 2020 | 09:06h | UTC

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure – SOLOIST-WHF – American College of Cardiology

 


#AHA20 – Randomized trial: Among patients with recurrent pericarditis, Rilonacept was associated with lower risk of pericarditis recurrence than placebo

18 Nov, 2020 | 09:04h | UTC

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Rilonacept Prevents Recurrent Pericarditis: RHAPSODY – TCTMD AND Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY – RHAPSODY – American College of Cardiology AND Trial shows drug effective in 96% of patients with recurrent pericarditis – Cleveland Clinic

 

Commentary on Twitter

 


The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease

18 Nov, 2020 | 09:03h | UTC

The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease – European Heart Journal

Original Guideline and commentary: 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease

 


Opinion: A new important study supports wider use of the polypill

18 Nov, 2020 | 09:01h | UTC

Richard Smith: A new important study supports wider use of the polypill – The Lancet

Original study and commentaries: Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

 

Commentary on Twitter

 


#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

16 Nov, 2020 | 02:03h | UTC

Polypill with or without Aspirin in Persons without Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)

News release: New study confirms combo pill alone and with aspirin lowers heart disease risk – American Heart Association

Commentaries: Polypill along with aspirin cuts heart attacks and strokes by up to 40%: International study – McMaster University AND Big study supports cheap combo pill to lower heart risks – Associated Press AND TIPS-3: International Study Looks at Benefits of Polypill and Polypill Plus Aspirin in Reducing CVD Risk – American College of Cardiology

 

Commentary on Twitter

 


#AHA20 – Randomized trial: In patients with atrial fibrillation and a bioprosthetic mitral valve, Rivaroxaban (20 mg) was noninferior to Warfarin (INR 2-3) for death, MACE, or major bleeding at 12 months

16 Nov, 2020 | 02:01h | UTC

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF – American Heart Association

Commentaries: Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib – TCTMD AND Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation – RIVER – American College of Cardiology AND Rivaroxaban Noninferior to Warfarin for Atrial Fibrillation in Patients with Bioprosthetic Mitral Valves – NEJM Journal Watch

 

Commentary on Twitter

 


#AHA20 – Randomized trial: In patients with systolic heart failure, Cardiac Myosin activation with Omecamtiv Mecarbil led to modest reduction in heart failure events

16 Nov, 2020 | 02:00h | UTC

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF – TCTMD AND Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure – GALACTIC-HF – American College of Cardiology

 

Commentary on Twitter

 


#AHA20 – Randomized trial: In patients with refractory hypercholesterolemia, the use of Evinacumab significantly reduced the LDL levels. Larger studies with patient-relevant outcomes are needed.

16 Nov, 2020 | 01:59h | UTC

Evinacumab in Patients with Refractory Hypercholesterolemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Evinacumab in Patients With Refractory Hypercholesterolemia – Evinacumab for Refractory Hypercholesterolemia – American College of Cardiology

 

Commentary on Twitter

 


#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

16 Nov, 2020 | 01:57h | UTC

Side effects often attributed to statins were the same for those taking a placebo – American Heart Association

Commentary: ‘Nocebo effect’ cause of most statin side-effects, study suggests – The Guardian

Original study: N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects – New England Journal of Medicine ($ – no abstract available)

 

Commentary on Twitter

 


#AHA20 – A small phase 2 randomized trial showed significantly improved survival with an early ECMO-facilitated resuscitation for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation

16 Nov, 2020 | 01:56h | UTC

Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial – The Lancet

Commentaries: Early ECMO-Facilitated Resuscitation for Out-of-Hospital Cardiac Arrest – NEJM Journal Watch AND Advanced REperfusion STrategies for refractory cardiac arrest – ARREST – American College of Cardiology AND Cardiac arrest treatment that uses life support machine boosts survival – NIH News Releases

 

Commentary on Twitter

 


#AHA20 – Randomized trial: In elective percutaneous coronary intervention Clopidogrel led to similar outcomes compared with Ticagrelor with less minor bleeding

16 Nov, 2020 | 01:55h | UTC

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial – The Lancet

News release: Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty – American Heart Association

Commentaries: Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS – TCTMD AND Ticagrelor Not Superior to Clopidogrel for Elective PCI – NEJM Journal Watch

 

Commentary on Twitter

 


#AHA20 – In patients hospitalized for heart failure with iron deficiency, intravenous Ferric carboxymaltose at discharge reduced the risk of heart failure rehospitalizations

16 Nov, 2020 | 01:53h | UTC

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial – The Lancet

Commentaries: Intravenous iron reduced rehospitalization risk in people with heart failure – American Heart Association AND AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF – TCTMD

 

Commentary on Twitter

 


#AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk

16 Nov, 2020 | 01:51h | UTC

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial – JAMA

Editorial 1: Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo?

Editorial 2: Do Omega-3 Fatty Acids Benefit Health?

Commentary: STRENGTH trial finds new fish oil medication did not reduce the risk of cardiac events – American Heart Association

 

Commentary on Twitter

 


[Not Published Yet] #AHA20 – Randomized trial: Fish oil and vitamin D supplements not effective for preventing atrial fibrillation

16 Nov, 2020 | 01:49h | UTC

Fish oil and vitamin D supplements not effective for preventing atrial fibrillation – American Heart Association

Commentary: Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm – TCTMD

 


USPSTF Statement: Insufficient evidence to recommend screening for high blood pressure in children and adolescents

11 Nov, 2020 | 09:14h | UTC

Screening for High Blood Pressure in Children and Adolescents – U.S. Preventive Services Task Force

Editorial: An Alternative View of Childhood Blood Pressure Screening: Reframing the Question – JAMA Network Open

Author interview: USPSTF Recommendation: Screening for Hypertension in Children and Adolescents

JAMA Patient Page: Screening for High Blood Pressure in Children and Adolescents

 


Patients with Covid-19 and myocardial injury have increased in-hospital mortality, particularly if echocardiographic abnormalities are present

10 Nov, 2020 | 09:37h | UTC

Characterization of Myocardial Injury in Patients With COVID-19 – Journal of the American College of Cardiology

Commentary: Study identifies cardiac structural damage experienced by COVID-19 patients – Mount Sinai Health System / News Medical

 


In patients hospitalized with COVID-19, right ventricular dilation or dysfunction was independently associated with a >2-fold increase in risk for mortality

10 Nov, 2020 | 09:36h | UTC

Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19 – Journal of the American College of Cardiology

Commentaries: Utility of RV Remodeling Over Risk Stratification in COVID-19 – American College of Cardiology AND Damage to heart’s right ventricle predicts a greater chance of death from COVID-19 – Weill Cornell Medical College

 


[Abstract Only] Randomized trial: In patients with persistent atrial fibrillation, treatment with catheter ablation + vein of Marshall ethanol infusion increased the likelihood of remaining free of AF, compared with catheter ablation alone

10 Nov, 2020 | 09:32h | UTC

Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic review: Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. “At present, there are no convincing data supporting any specific inotropic or vasodilating therapy to reduce mortality in hemodynamically unstable patients with CS or LCOS.”

10 Nov, 2020 | 09:30h | UTC

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome – Cochrane Library

 


Stay Updated in Your Specialty

 

No spam, just news.